| Zhou, Xin |
NCT05596721: Azithromycin Treatment for Non-eosinophilic Chest Tightness Variant Asthma |
|
|
| Not yet recruiting | 4 | 248 | RoW | Azithromycin, ICS/LABA | Second Affiliated Hospital, School of Medicine, Zhejiang University | Asthma, Chest Syndrome, Azithromycin, Effect of Drug | 03/24 | 03/24 | | |
NCT04263922: Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3 |
|
|
| Recruiting | 4 | 466 | RoW | Huaiqihuang granules, B12000050755, Valsartan capsule, H20030638 | The First Affiliated Hospital of Dalian Medical University, Huazhong University of Science and Technology, LinkDoc Technology (Beijing) Co. Ltd. | Renal Insufficiency, Chronic | 10/25 | 03/26 | | |
NCT05236621: A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma |
|
|
| Active, not recruiting | 3 | 85 | RoW | Pomalidomide, Dexamethasone | Qilu Pharmaceutical Co., Ltd. | Multiple Myeloma, Recurrent or Refractory | 06/22 | 12/23 | | |
RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 |
|
|
| Recruiting | 3 | 366 | RoW | RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda | RemeGen Co., Ltd. | Breast Cancer | 06/24 | 12/24 | | |
TORCHLIGHT, NCT04085276: Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment |
|
|
| Active, not recruiting | 3 | 531 | RoW | JS001, Nab-Paclitaxel, Placebo | Shanghai Junshi Bioscience Co., Ltd. | Triple-Negative Breast Cancer | 12/24 | 12/25 | | |
NCT06323213: Efficacy and Safety Study of 610 in Patients With Severe Asthma |
|
|
| Not yet recruiting | 3 | 480 | NA | 610, Placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Asthma | 06/26 | 09/26 | | |
BELIEVE-01, NCT05234684: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 3 | 150 | RoW | Orelabrutinib + R-CHOP, ICP-022+ R-CHOP, Placebo + R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Diffuse Large B Cell Lymphoma (DLBCL) | 07/24 | 12/25 | | |
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL |
|
|
| Recruiting | 3 | 218 | RoW | ICP-022, Chlorambucil, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 06/25 | | |
| Recruiting | 3 | 314 | RoW | Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Breast Cancer | 07/25 | 01/26 | | |
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) |
|
|
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/26 | 01/27 | | |
NCT06004856: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia |
|
|
| Recruiting | 3 | 195 | RoW | Orelabrutinib, Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Primary Immune Thrombocytopenia (ITP) | 12/25 | 04/26 | | |
LEONARDA-2, NCT05851014: A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer |
|
|
| Recruiting | 3 | 350 | RoW | GB491 combined with Letrozole, Placebo combined with Letrozole | Genor Biopharma Co., Ltd. | Breast Cancer | 01/26 | 01/27 | | |
NCT05232149: A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia |
|
|
| Recruiting | 2a/2b | 30 | RoW | Orelabrutinib( lower dose), Orelabrutinib( higher dose) | Beijing InnoCare Pharma Tech Co., Ltd. | Primary Immune Thrombocytopenia | 12/23 | 12/24 | | |
NCT05528679: A Phase II Study of 610 in Participants With Severe Eosinophilic Asthma |
|
|
| Not yet recruiting | 2 | 120 | RoW | 610 100mg, 610 300mg, placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Asthma | 09/23 | 09/23 | | |
NCT06438757: Trial of JYB1904 in Patients With Allergic Asthma |
|
|
| Recruiting | 2 | 60 | RoW | JYB1904, Omalizumab | Jemincare | Allergic Asthma | 10/25 | 10/25 | | |
NCT04835870: Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL |
|
|
| Recruiting | 2 | 78 | RoW | Zanubrutinib, BTK inhibitors, Rituximab, MabThera, Cyclophosphamide, CTX, Doxorubicin, ADM, Vincristine, VCR, Prednisone, Prednisonum | The First Affiliated Hospital of Soochow University | Non-GCB/ABC Diffuse Large B-Cell Lymphoma | 10/25 | 10/25 | | |
| Recruiting | 1/2 | 80 | RoW | TQB3454 Tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 06/25 | 12/25 | | |
NCT06122831: A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF) |
|
|
| Recruiting | 1/2 | 92 | RoW | TQ05105 Tablets, TQB3617 Capsules | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Myelofibrosis | 12/26 | 04/27 | | |
NCT05584306: A Dose Ranging Placebo-controlled Double-blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of 610 in Participants With Severe Eosinophilic Asthma |
|
|
| Active, not recruiting | 1 | 24 | RoW | 610 30mg group, 610 100mg group, 610 300mg group, Placebo 30mg group, Placebo 100mg group, Placebo 300mg group | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Asthma | 09/23 | 09/23 | | |
ELPVQFLACS, NCT06517095: Revised Capsular Polishing and Its Impact on the Positioning of the Intraocular Lens and Visual Quality Following Femtosecond Laser-assisted Cataract Surgery |
|
|
| Withdrawn | N/A | 70 | RoW | improved capsular polishing, the conventional I/A polishing | Xi'an People's Hospital (Xi'an Fourth Hospital) | Cataract | 12/25 | 12/25 | | |
NCT04417946: Peer-led Social Media Intervention to Prevent HIV Among Young Men Who Have Sex With Men (YMSM) |
|
|
| Completed | N/A | 227 | US | PrEP messages, Heath messages | Yale University, Substance Abuse and Mental Health Services Administration (SAMHSA) | Pre-Exposure Prophylaxis, Hiv, Men | 04/23 | 04/23 | | |
| Active, not recruiting | N/A | 482 | RoW | | Takeda | Multiple Myeloma, Neoplasms, Plasma Cell | 09/25 | 09/25 | | |
NCT06648317: Radiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung Lesions |
|
|
| Recruiting | N/A | 20 | RoW | FDG-PET | Peking University Cancer Hospital & Institute | Lung Cancer, Non-Small Cell, Lung Infection | 03/25 | 12/25 | | |
| Lu, Wei |
UplighTED, NCT06307626: A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults with Thyroid Eye Disease. |
|
|
| Recruiting | 3 | 108 | Europe, Japan, US, RoW | Efgartigimod PH20 SC, Placebo PH20 SC | argenx | Thyroid Eye Disease | 02/26 | 10/27 | | |
NCT05251662: Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 90 | RoW | Sintilimab, IBI305, Bevacizumab Biosimilar, GEMOX | Tianjin Medical University Cancer Institute and Hospital | Intrahepatic Cholangiocarcinoma | 01/24 | 01/25 | | |
NCT05651672: Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations |
|
|
| Recruiting | 2 | 100 | RoW | Pemigatinib, Pemazyre | Tianjin Medical University Cancer Institute and Hospital | Gastrointestinal Cancer | 12/24 | 12/26 | | |
NCT06044350: A Clinical Trial of BAT4406F Injection in Patients with Neuromyelitis Optica Spectrum Disorders |
|
|
| Recruiting | 2 | 162 | RoW | BAT4406F Injection, BAT4406F Placebos | Bio-Thera Solutions | Optic Neuromyelitis Spectrum Disease | 05/25 | 05/26 | | |
NCT05678270: A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 70 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Intrahepatic Cholangiocarcinoma (ICC) | 05/26 | 12/26 | | |
NCT06310590: Safety and Efficacy of NRT6003 in Patients With Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 1 | 40 | RoW | NRT6003 Injection, Yttrium-90 carbon microspheres | Chengdu New Radiomedicine Technology Co. LTD. | Unresectable Hepatocellular Carcinoma | 10/25 | 10/25 | | |
NCT05776121: Study of ZB001 in Chinese Patients With Thyroid Eye Disease |
|
|
| Active, not recruiting | 1 | 17 | RoW | ZB001 for injection | Zenas BioPharma (USA), LLC | Thyroid Eye Disease | 10/24 | 10/24 | | |
NCT06047431: A Study of QL1706H in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 150 | NA | QL1706H | Qilu Pharmaceutical Co., Ltd. | Advanced Solid Tumors | 12/24 | 12/25 | | |
| Recruiting | N/A | 120 | RoW | early APM, Early arthroscopic partial meniscectomy, delayed APM, delayed arthroscopic partial meniscectomy | The First People's Hospital of Jingzhou | Meniscus Tear | 12/22 | 12/22 | | |
NCT05711459: Bicyclol in the Treatment of Antineoplastic Drug-induced Liver Injury. |
|
|
| Recruiting | N/A | 5405 | RoW | Bicyclol tablets | Tianjin Medical University Cancer Institute and Hospital | Drug-Induced Acute Liver Injury | 05/23 | 05/24 | | |
NCT05215665: GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma |
|
|
| Recruiting | N/A | 146 | RoW | GEMOX Regimen, Lenvatinib, Toripalimab | Tianjin Medical University Cancer Institute and Hospital | Cholangiocarcinoma | 05/24 | 01/26 | | |
NCT06292715: Microwave Ablation With Splenic Artery Occlusion for Secondary Hypersplenism |
|
|
| Recruiting | N/A | 35 | RoW | microwave ablation of the spleen, Splenic artery balloon implantation | Tianjin Medical University Cancer Institute and Hospital | Secondary Hypersplenism | 12/25 | 12/26 | | |
NCT05791604: The Intervention of Obesity in Children With Prader-Willi Syndrome Using Prebiotics and Probiotics |
|
|
| Recruiting | N/A | 60 | RoW | probiotics including B. lactis B420, B. lactis HN019, B. animalis Bb-12, L. rhamnosus GG, Prebiotics with galactomannan and oligofructose | Children's Hospital of Fudan University | Prader-Willi Syndrome | 03/26 | 07/26 | | |
| Li, Yufeng |
NCT05102149: Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus |
|
|
| Recruiting | 3 | 672 | RoW | PB-201, Vildagliptin, PB-201 matched placebo, Vildagliptin matched placebo | PegBio Co., Ltd. | Type 2 Diabetes Mellitus (T2DM) | 11/23 | 04/25 | | |
NCT06350890: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes |
|
|
| Active, not recruiting | 3 | 408 | RoW | HTD1801, berberine ursodeoxycholate, Placebo | HighTide Biopharma Pty Ltd | T2DM (Type 2 Diabetes Mellitus) | 03/25 | 09/25 | | |
Symphony2, NCT06353347: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 551 | RoW | HTD1801, berberine ursodeoxycholate, Placebo | HighTide Biopharma Pty Ltd | Type 2 Diabetes Mellitus | 03/25 | 12/25 | | |
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time |
|
|
| Completed | 3 | 928 | Europe, Canada, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company | Diabetes, Type 2 Diabetes | 04/24 | 04/24 | | |
NCT05352516 / 2022-002188-31: A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture |
|
|
| Completed | 3 | 514 | RoW | HLX14, Prolia® | Shanghai Henlius Biotech, Shanghai Henlius Biotech, Inc. | Postmenopausal | 12/23 | 07/24 | | |
| Completed | 3 | 257 | RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Diabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases | 07/24 | 07/24 | | |
NCT06696261: A Study of Lianxiaxiaopi Granules in the Treatment of Postprandial Distress Syndrome |
|
|
| Not yet recruiting | 3 | 342 | RoW | Lianxiaxiaopi Granules, a simulated agent of Lianxiaxiaopi Granules | Tasly Pharmaceutical Group Co., Ltd | Postprandial Distress Syndrome | 06/26 | 08/26 | | |
ACHIEVE-1, NCT05971940: A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone |
|
|
| Active, not recruiting | 3 | 520 | Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Type 2 Diabetes | 04/25 | 04/25 | | |
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 1576 | Japan, US, RoW | Orforglipron, LY3502970, Semaglutide | Eli Lilly and Company | Type 2 Diabetes | 09/25 | 09/25 | | |
NCT05850546: Rituximab in the First Episode of Paediatric Nephrotic Syndrome |
|
|
| Not yet recruiting | 3 | 138 | RoW | Rituximab, rituximab biosimilar (HANLIKANG®, Shanghai Henlius Biotech, Inc. China), Corticosteroid, prednisolone/prednisone | Children's Hospital of Fudan University, Shanghai Shen Kang Hospital Development Center, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Children's Medical Center, Shanghai Children's Hospital | Steroid-Sensitive Nephrotic Syndrome | 05/26 | 09/26 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
NCT05227677: Value of Glycated Albumin in Intervention of Glycemic Control in Chinese Patients With Type 2 Diabetes |
|
|
| Active, not recruiting | N/A | 200 | RoW | GA guided anti-diabetic therapy adjustment, current guidelines to adjust treatment | Asahi Kasei Pharma Corporation | Type 2 Diabetes Mellitus | 08/24 | 12/24 | | |
NCT04588025: Disposable Perfusion Phantom for Accurate DCE (Dynamic Contrast Enhanced)-MRI Measurement of Pancreatic Cancer Therapy Response |
|
|
| Recruiting | N/A | 55 | US | Point-of-care Portable Perfusion Phantom, P4 | University of Alabama at Birmingham | Pancreatic Cancer | 10/25 | 10/26 | | |
NCT05866029: Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture |
|
|
| Recruiting | N/A | 2478 | RoW | Denosumab, Teriparatide | Peking Union Medical College Hospital | Osteoporotic Fractures | 09/26 | 09/26 | | |
| Li, Gang |
HEARTRIP, NCT03809273: Effects of Yangxinshi Pills on the Exercise Tolerance Compared With Trimetazidine in Patients After PCI |
|
|
| Recruiting | 4 | 668 | RoW | Yangxinshi, Trimetazidine, Yangxinshi mimic, Trimetazidine mimic | Shenyang Northern Hospital | Percutaneous Coronary Intervention | 12/20 | 12/20 | | |
| Active, not recruiting | 4 | 948 | Europe, Canada, US, RoW | Edoxaban, Lixiana, Savaysa, Non-anticoagulant medical therapy | Population Health Research Institute | Intracranial Hemorrhages, Atrial Fibrillation | 04/26 | 10/26 | | |
NCT05182463: Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients |
|
|
| Recruiting | 4 | 5000 | RoW | Peginterferon Alfa-2B, Nucleoside Analogs | Third Affiliated Hospital, Sun Yat-Sen University | Hepatitis B, Chronic | 12/26 | 11/29 | | |
| Completed | 3 | 2425 | RoW | urapidil, Intensive BP lowing | The George Institute for Global Health, China, Shanghai East Hospital, China, First Affiliated Hospital of Chengdu Medical College, China, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, China | Stroke, Acute, Cerebrovascular Disorders | 11/23 | 11/23 | | |
EAST, NCT06773364: Early Initiated Ambulance-delivered Levetiracetam and Headposition in Hyper-acute Stroke Trial |
|
|
| Not yet recruiting | 3 | 2423 | NA | Levetiracetam, Guide-recommended management, The lying flat (0°) head position, The sitting-up (≥30°) head position | Shanghai East Hospital | Suspected Stroke | 12/28 | 12/29 | | |
ATEM, NCT05416476: Anisodine Hydrobromide For The Preventive Treatment Of Episodic Migraine |
|
|
| Recruiting | 3 | 288 | RoW | Anisodine Hydrobromide, Anisodine Hydrobromide placebo | Second Affiliated Hospital, School of Medicine, Zhejiang University | Migraine Without Aura, Migraine With Aura | 10/25 | 12/25 | | |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
| Completed | 2 | 200 | RoW | Intravenous tirofiban combination therapy, Tirofiban | Shanghai East Hospital, Shanghai 6th People's Hospital, Ningbo No. 1 Hospital, Zhangzhou Municipal Hospital of Fujian Province, Shanghai 7th People's Hospital, Jinan Central Hospital, Xuchang Central Hospital | Ischemic Stroke | 07/23 | 10/23 | | |
PANDORA, NCT04995016: Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma |
|
|
| Not yet recruiting | 2 | 18 | RoW | Pembrolizumab, Keytruda, Axitinib, Inlyta | Tianjin Medical University Second Hospital | Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma | 08/22 | 08/23 | | |
| Recruiting | 1/2 | 380 | RoW | PM8002 | Biotheus Inc. | Malignant Neoplasm | 11/25 | 11/25 | | |
NCT04093336: Effect of Mesenchymal Stem Cells(MSCs) Transplantation for Acute Cerebral Infarction Patients |
|
|
| Recruiting | 1/2 | 120 | RoW | human umbilical cord mesenchymal stem cells, Placebo, standardized treatment | Shanghai East Hospital | Infarction, Middle Cerebral Artery, Infarction, Anterior Cerebral Artery, Cerebral Infarction, Stroke, Ischemic, Acute Stroke, Brain Infarction, Infarction, PCA, Infarction, Posterior Circulation, Brain | 12/24 | 12/24 | | |
NCT04137926: A Multicenter Study on the Diagnosis and Intervention of New Biomarkers on the Prodromal Stage of Alzheimer's Disease |
|
|
| Recruiting | N/A | 360 | RoW | MicRNAs battery | Shanghai Mental Health Center | Alzheimer's Disease | 08/22 | 11/22 | | |
NCT06468436: Dexmedetomidine-Esketamine Combination for Sedation and Analgesia in ICU Patients |
|
|
| Not yet recruiting | N/A | 1508 | RoW | Dexmedetomidine-Esketamine Combination, Dexmedetomidine hydrochloride, Esketamine hydrochloride, Dexmedetomidine | Peking University First Hospital, Peking University International Hospital, Tianjin Medical University General Hospital | Aged, Intensive Care Units, Ventilators, Mechanical, Dexmedetomidine, Esketamine, Delirium | 06/30 | 12/30 | | |
NCT05755776: The Efficacy and Safety of Tenofovir Amibufenamide to Treat Low-level Viraemia After Entecavir Treatment |
|
|
| Recruiting | N/A | 204 | RoW | TMF, Heng Mu | The Second Affiliated Hospital of Chongqing Medical University, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Chronic Hepatitis B | 12/24 | 12/24 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
| Sun, Jian |
NCT05212051: Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active AS |
|
|
| Recruiting | 2 | 120 | RoW | JS005, Recombinant humanized anti-IL-17A monoclonal antibody injection, Placebo | Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH | Active Ankylosing Spondylitis | 11/22 | 01/23 | | |
NCT05242588: Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active Nr-axSpA |
|
|
| Recruiting | 2 | 120 | RoW | JS005, Recombinant humanized anti-IL-17A monoclonal antibody injection, Placebo | Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH | Non-radiographic Axial Spondyloarthritis | 04/23 | 06/23 | | |
NCT04996329: Early Health Warning Intervention in Tobacco Control |
|
|
| Recruiting | N/A | 1000 | RoW | early health warning intervention | Peking University First Hospital, The Second Hospital of Hebei Medical University, Henan Provincial People's Hospital, Second Hospital of Jilin University, First Affiliated Hospital Xi'an Jiaotong University, Shandong Provincial Hospital, Shanxi Bethune Hospital, Tianjin Medical University General Hospital, The Affiliated Hospital of Inner Mongolia Medical University, The First Hospital of Qinhuangdao | Smoking Cessation | 12/22 | 12/22 | | |
NCT06340295: A Multicenter, Prospective Cohort Study of Preserved Ratio Impaired Spirometry(PRISm) in a Population |
|
|
| Recruiting | N/A | 2000 | RoW | | Peking University First Hospital, Shanxi Bethune Hospital, First Affiliated Hospital Xi'an Jiaotong University, Tianjin Medical University General Hospital, The First Hospital of Qinhuangdao, Shandong Provincial Hospital, Second Hospital of Jilin University, People's Hospital of Xinjiang Uygur Autonomous Region, MinDong Hospital of Ningde City | COPD | 05/26 | 05/26 | | |
SCDB, NCT06422845: Peripheral Scoring Drug-coated Balloon in the Treatment of Hemodialysis Arteriovenous Fistula Stenosis |
|
|
| Recruiting | N/A | 328 | RoW | Dissolve AV Peripheral Scoring Drug-coated Balloon, Scoring Drug-coated Balloon | DK Medical Technology (Suzhou) Co., Ltd. | Arteriovenous Fistula Stenosis | 07/27 | 07/27 | | |
NCT05652517: Univu-guided Vein of Marshall Ethanol Infusion (Marshall-Merge) |
|
|
| Recruiting | N/A | 100 | RoW | Vein of Marshall ethanol infusion | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation | 12/24 | 12/25 | | |
NCT04937283: Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm |
|
|
| Recruiting | N/A | 690 | RoW | Segmentectomy with systemic lymph node dissection, Lobectomy with hilar and mediastinal lymph node dissection | Shanghai Pulmonary Hospital, Shanghai, China | Lung Adenocarcinoma | 12/28 | 12/28 | | |
| Li, Fei |
| Recruiting | 4 | 200 | RoW | Oral bifidobacterium triple live powder, Conventional treatment, Sunbathing, Sunbathing and the Oral bifidobacterium triple live powder | Zhuhai Center for Maternal and Child Health Care, Children's Hospital of Chongqing Medical University | Hyperbilirubinemia, Neonatal | 06/24 | 06/24 | | |
RESCUE-GC, NCT02867839: Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer |
|
|
| Terminated | 3 | 29 | RoW | Oxaliplatin plus S-1, SOX, S-1 only, S-1 | Peking University Cancer Hospital & Institute | Gastric Cancer | 09/21 | 09/21 | | |
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 08/23 | 05/27 | | |
| Recruiting | 3 | 240 | RoW | Equecabtagene Autoleucel Injection, FUCASO, Daratumumab, Pomalidomide, Bortezomib, Dexamethasone | Nanjing IASO Biotechnology Co., Ltd. | Multiple Myeloma | 08/27 | 12/30 | | |
NCT06521255: Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
|
|
| Recruiting | 3 | 244 | RoW | Tafasitamab, Lenalidomide, Gemcitabine, Oxaliplatin, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | DLBCL | 09/28 | 12/29 | | |
NCT06363994: A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL |
|
|
| Recruiting | 3 | 476 | RoW | Orelabrutinib, Bendamustine Injection, Rituximab, Orelabrutinib Placebo | InnoCare Pharma Inc. | Mantle Cell Lymphoma | 06/31 | 06/32 | | |
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | 3 | 150 | RoW | SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) | Antengene Corporation | Relapsed or Refractory Multiple Myeloma | 07/24 | 10/24 | | |
BELIEVE-01, NCT05234684: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 3 | 150 | RoW | Orelabrutinib + R-CHOP, ICP-022+ R-CHOP, Placebo + R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Diffuse Large B Cell Lymphoma (DLBCL) | 07/24 | 12/25 | | |
| Recruiting | 3 | 225 | Europe, Canada, Japan, US, RoW | Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B) | F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi | Invasive Aspergillosis | 09/25 | 11/26 | | |
| Recruiting | 3 | 357 | Europe, Japan, US, RoW | Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib | GlaxoSmithKline | Multiple Myeloma | 01/24 | 05/29 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
CMML1-2, NCT06647862: IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia |
|
|
| Recruiting | 3 | 170 | RoW | IMM01, Timdarpacept, Azacitidine, Placebo | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Chronic Myelomonocytic Leukemia | 10/26 | 10/29 | | |
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/25 | 08/26 | | |
TQ05105-III-01, NCT06682169: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease |
|
|
| Recruiting | 3 | 182 | RoW | Rovadicitinib, Imatinib, Methotrexate, Mycophenolate mofetil, Rituximab | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Graft-versus-host Disease | 10/29 | 12/30 | | |
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL |
|
|
| Recruiting | 3 | 218 | RoW | ICP-022, Chlorambucil, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 06/25 | | |
NCT05051891: A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 356 | RoW | Orelabrutinib and R-CHOP, R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Treatment-naїve Mantle Cell Lymphoma | 12/24 | 12/27 | | |
| Active, not recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa | Loxo Oncology, Inc., Eli Lilly and Company | Lymphoma, Mantle-Cell | 12/25 | 07/26 | | |
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
|
|
| Active, not recruiting | 3 | 440 | Europe, Canada, Japan, US, RoW | Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin | ADC Therapeutics S.A., ADC Therapeutics SA | Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | 06/25 | 06/28 | | |
|
|
|
DESTINY, NCT05334368: Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial |
|
|
| Recruiting | 3 | 120 | Europe, Canada, Japan, US, RoW | Depemokimab, Placebo | GlaxoSmithKline | Hypereosinophilic Syndrome | 02/26 | 03/26 | | |
NCT05709093: A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS) |
|
|
| Recruiting | 3 | 552 | RoW | Lemzoparlimab+Azacitidine (AZA), Azacitidine (AZA) | TJ Biopharma Co., Ltd. | Myelodysplastic Syndromes(MDS) | 03/27 | 03/27 | | |
NCT06082102: Efficacy and Safety of Orelabrutinib Plus Lenalidomide and Rituximab (R2) Compared to Placebo Plus R2 in r/r Marginal Zone Lymphoma |
|
|
| Recruiting | 3 | 324 | RoW | Orelabrutinib, Lenalidomide, Rituximab, Orelabrutinib Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Relapsed/Refractory Marginal Zone Lymphoma | 08/27 | 02/30 | | |
| Active, not recruiting | 3 | 650 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma | 06/25 | 01/28 | | |
NCT04453345: TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL |
|
|
| Recruiting | 2/3 | 42 | RoW | thalidomide + prednisone + methotrexate, TPM regimen | Institute of Hematology & Blood Diseases Hospital, The First Affiliated Hospital of Nanchang University, First Affiliated Hospital of Guangxi Medical University, Henan Cancer Hospital, First Hospital of Jilin University, Central South University, Tianjin First Central Hospital | T-LGL Leukemia, Clpd-Nk | 05/23 | 05/25 | | |
| Recruiting | 2/3 | 142 | RoW | avatrombopag, Doptelet, Placebo | Peking University People's Hospital, Xiangya Hospital of Central South University, Sichuan Provincial People's Hospital, First Affiliated Hospital of Harbin Medical University, The First Affiliated Hospital of Zhengzhou University, First Affiliated Hospital of Xinjiang Medical University, Shanxi Bethune Hospital, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Tang-Du Hospital, The First Affiliated Hospital of Nanchang University | Thrombocytopenia, Stem Cell Transplant Complications | 10/24 | 10/25 | | |
ICP-CL-01203, NCT06378138: ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
|
|
| Recruiting | 2/3 | 226 | RoW | ICP-248, Orelabrutinib | Beijing InnoCare Pharma Tech Co., Ltd. | Hematologic Malignancies | 11/30 | 07/31 | | |
NCT05927792: Efficacy and Mechanism of Repetitive Transcranial Magnetic Stimulation in Children With Autism Spectrum Disorders |
|
|
| Recruiting | 2/3 | 200 | RoW | repeated transcranial magnetic stimulation (continuous theta-burst stimulation), sham repeated transcranial magnetic stimulation | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Mental Health Center, Zhengzhou Children's Hospital, China, Qilu Hospital of Shandong University | Autism Spectrum Disorder | 09/25 | 12/25 | | |
wAIHA, NCT05535933: HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia |
|
|
| Recruiting | 2/3 | 110 | RoW | HMPL-523(300mg PO QD), Sovleplenib, Placebo | Hutchison Medipharma Limited | Warm Antibody Autoimmune Hemolytic Anemia | 09/26 | 11/26 | | |
NCT06511895: AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27) |
|
|
| Recruiting | 2 | 150 | RoW | AZD4205 | Dizal Pharmaceuticals | Peripheral T Cell Lymphoma | 05/25 | 12/26 | | |
NCT03837873: DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma |
|
|
| Recruiting | 2 | 118 | RoW | Rituximab, Etoposide, Vincristine, Doxorubicin, Dexamethasone, Cyclophosphamide, Lenalidomide, Cisplatin, Cytarabine | Institute of Hematology & Blood Diseases Hospital | Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma | 09/23 | 09/24 | | |
